Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 15/20 | 0.44 |
| ▸ | PLAU | P00749 | 15/20 | 0.44 |
| ▸ | F10 | P00742 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 13/20 | 0.42 |
| ▸ | PLAT | P00750 | 8/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963255 | 0.97 | PLG (0.41) | PLGPLAUF10F2PLAT | |
| SCHEMBL1509477 | 0.89 | F10 (0.38) | PLGPLAUF10F2PLAT | |
| SCHEMBL4963532 | 0.87 | HDAC6 (0.50) | PLGPLAUF10F2PLAT | |
| SCHEMBL1509505 | 0.86 | NAMPT (0.36) | PLGPLAUF10F2PLAT | |
| SCHEMBL4960666 | 0.79 | PLG (0.40) | PLGPLAUF10F2PLAT | |
| SCHEMBL12834016 | 0.78 | NAMPT (0.47) | PLGPLAUF10F2PLAT | |
| SCHEMBL1509535 | 0.77 | NAMPT (0.45) | PLGPLAUF10F2PLAT | |
| SCHEMBL14091684 | 0.76 | PBK (0.40) | PLGPLAUF10F2PLAT | |
| SCHEMBL4963266 | 0.74 | HDAC6 (0.47) | PLGPLAUF10F2PLAT | |
| SCHEMBL4965597 | 0.74 | HDAC6 (0.47) | PLGPLAUF10F2PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | PLG 4217/4885PLAU 3843/4885F10 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.